BPLPHARMA vs CORONA: Stock Comparison
BHARAT PARENTERALS shows a lower P/E, while CORONA REMEDIES shows a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BPLPHARMA leads 3; CORONA leads 4 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Live Price | ₹1,547 | ₹2,152.5 |
| Day Change | 2.46% | 0.42% |
| Volume | 23 | 6,287 |
| 52-Week High | ₹1,649 | ₹2,292.4 |
| 52-Week Low | ₹1,125.7 | ₹1,336.6 |
| Distance from 52W High | -6.19% | -6.1% |
Valuation
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Market Cap | ₹0 Cr | ₹13,087 Cr |
| P/E Ratio | 0x | 66.97x |
| P/B Ratio | 3.18x | 17.84x |
| EPS | ₹5.31 | ₹9.83 |
| Book Value | ₹452.09 | ₹122.12 |
| Dividend Yield | 0.13% | 0.46% |
Growth
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -40.79% | 0% |
| Qtr Profit Growth | 202.63% | -0.02% |
Profitability & Leverage
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| ROE | — | 24.28% |
| ROCE | — | 20.94% |
| Net Margin | 0% | 13.19% |
| Operating Margin | — | 15.89% |
| Debt to Equity | — | 0.19x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Promoter Holding | 67.2%▲ 0.03 pp | 69% |
| FII Holding | 0.11% | 3.63%▲ 1.38 pp |
| DII Holding | 1.37%▲ 0.31 pp | 12.9%▲ 5.88 pp |
| Public Holding | 31.31%▼ 0.35 pp | 14.48%▼ 7.26 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BHARAT PARENTERALS and CORONA REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.